The pathogenesis and treatment of acute spinal cord injuries in dogs

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 5, 2010, Pages 791-807

  Olby, Natasha ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Infarct; Methylprednisolone; Polyethylene glycol; Primary damage; Secondary damage; Spinal cord trauma

Indexed keywords

4 AMINOPYRIDINE; 4 AMINOPYRIDINE DERIVATIVE; ACETYLCYSTEINE; AMINOCAPROIC ACID; CYCLOSPORIN A; DEXAMETHASONE; DIMETHYL SULFOXIDE; GACYCLIDINE; GANGLIOSIDE; GANGLIOSIDE GM1; MACROGOL; METHYLPREDNISOLONE ACETATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; NALOXONE; NIFEDIPINE; NIMODIPINE; OPIATE ANTAGONIST; OXYGEN; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PROTIRELIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RILUZOLE; TACROLIMUS; TEMPOL; TIRILAZAD; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; UNINDEXED DRUG; URIC ACID;

APOPTOSIS; BLOOD PRESSURE REGULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DOG; DRUG DOSE ESCALATION; EXCITOTOXICITY; HUMAN; INTERVERTEBRAL DISK HERNIA; INTERVERTEBRAL DISKECTOMY; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELITIS; NERVE STIMULATION; NEUROPROTECTION; NONHUMAN; OLFACTORY ENSHEATHING CELL; OXYGENATION; PATHOGENESIS; REVIEW; SCAR FORMATION; SPINAL CORD DECOMPRESSION; SPINAL CORD INJURY; SPINAL CORD ISCHEMIA; SPINE STABILIZATION; SYRINGOMYELIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DOGS; FEMALE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELITIS; NEUROPROTECTIVE AGENTS; SPINAL CORD INJURIES; SPINAL CORD REGENERATION; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 77955884085     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.05.007     Document Type: Review

References (87)

1. Rowland J.W., Hawryluk G.W., Kwon B., et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus 2008, 25(5):E2.
2. Baptiste D.C., Fehlings M.G. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006, 23(3-4):318-334.
3. Olby N.J. Current concepts in the management of acute spinal cord injury. J Vet Intern Med 1999, 13:399-407.
4. Hawryluk G.W., Rowland J., Kwon B.K., et al. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008, 25(5):E14.
5. Fish C.J., Blakemore W.F. A model of chronic spinal cord compression in the cat. Neuropathol Appl Neurobiol 1983, 9:109-119.
6. Shi R., Blight A.R. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure. J Neurophysiol 1996, 76:1572-1580.
7. Smith P.M., Jeffery N.D. Histological and ultrastructural analysis of white matter damage after naturally-occurring spinal cord injury. Brain Pathol 2006, 16:99-109.
8. Griffiths I.R. Spinal cord injuries: a pathological study of naturally occurring lesions in the dog and cat. J Comp Pathol 1978, 88(2):303-315.
9. Jeffery N.D., Lakatos A., Franklin R.J. Autologous olfactory glial cell transplantation is reliable and safe in naturally occurring canine spinal cord injury. J Neurotrauma 2005, 22(11):1282-1293.
10. Olby N.J., Humphrey J., Spinapolice K., et al. Phase 1 clinical trial of 4-aminopyridine derivatives in dogs with chronic myelopathies [abstract]. J Vet Intern Med 2008, 22:722.
11. Furlan J.C., Noonan V., Cadotte D.W., et al. Timing of decompressive surgery after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies. J Neurotrauma 2010, [Epub ahead of print].
12. Tator C.H., Fehlings M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991, 75(1):15-26.
13. Balentine J.D. Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab Invest 1978, 39(3):236-253.
14. Gerzanich V., Woo S.K., Vennekens R., et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat Med 2009, 15(2):185-191.
15. Guha A., Tator C.H. Acute cardiovascular effects of experimental spinal cord injury. J Trauma 1988, 28(4):481-490.
16. Griffiths I.R., Trench J.G., Crawford R.A. Spinal cord blood flow and conduction during experimental cord compression in normotensive and hypotensive dogs. J Neurosurg 1979, 50(3):353-360.
17. Rabinowitz R.S., Eck J.C., Harper C.M., et al. Urgent surgical decompression compared to methylprednisolone for the treatment of acute spinal cord injury: a randomized prospective study in beagle dogs. Spine (Phila Pa 1976) 2008, 33(21):2260-2268.
18. Parker A.J., Smith C.W. Functional recovery from spinal cord trauma following delayed incision of spinal meninges in dogs. Res Vet Sci 1975, 18(1):110-112.
19. Loughin C.A., Dewey C.W., Ringwood P.B., et al. Effect of durotomy on functional outcome of dogs with type I thoracolumbar disc extrusion and absent deep pain perception. Vet Comp Orthop Traumatol 2005, 18(3):141-146.
20. Kwon B.K., Curt A., Belanger L.M., et al. Intrathecal pressure monitoring and cerebrospinal fluid drainage in acute spinal cord injury: a prospective randomized trial. J Neurosurg Spine 2009, 10(3):181-193.
21. Park E., Velumian A.A., Fehlings M.G. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 2004, 21(6):754-774.
22. Olby N.J., Sharp N.J., Muñana K.R., et al. Chronic and acute compressive spinal cord lesions in dogs due to intervertebral disc herniation are associated with elevation in lumbar cerebrospinal fluid glutamate concentration. J Neurotrauma 1999, 16(12):1215-1224.
23. Petitjean M.E., Pointillart V., Dixmerias F., et al. Medical treatment of spinal cord injury in the acute stage. Ann Fr Anesth Reanim 1998, 17:114-122.
24. Ates O., Cayli S.R., Gurses I., et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007, 14(7):658-665.
25. Tadie M., D'Arbigny P., Mathe J., et al. Acute spinal cord injury. Early care and treatment in a multicenter study with gacyclidine. Soc Neurosci 1999, 25:1090.
26. Demopoulos H.B., Flamm E.S., Pietronigro D.D., et al. The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand Suppl 1980, 492:91-119.
27. Genovese T., Cuzzocrea S. Role of free radicals and poly (ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr Med Chem 2008, 15(5):477-487.
28. Xiong Y., Hall E.D. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp Neurol 2009, 216(1):105-114.
29. Hall E.D. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992, 76(1):13-22.
30. Bracken M.B., Shepard M.J., Holford T.R., et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277(20):1597-1604.
31. Bracken M.B., Shepard M.J., Holford T.R., et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998 Nov, 89(5):699-706.
32. Bracken M.B., Shepard M.J., Collins W.F., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990, 322(20):1405-1411.
33. Bracken M.B., Shepard M.J., Hellenbrand K.G., et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg 1985, 63(5):704-713.
34. Coleman W.P., Benzel D., Cahill D.W., et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000, 13(3):185-199.
35. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000, 93(Suppl 1):1-7.
36. Nesathurai S. Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma 1998, 45(6):1088-1093.
37. Scott G.S., Cuzzocrea S., Genovese T., et al. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 2005, 102(9):3483-3488.
38. Coates J.R., Sorjonen D.C., Simpson S.T., et al. Clinicopathologic effects of a 21-aminosteroid compound (U74389G) and high-dose methylprednisolone on spinal cord function after simulated spinal cord trauma. Vet Surg 1995, 24:128-139.
39. Baltzer W.I., McMichael M.A., Hosgood G.L., et al. Randomized, blinded, placebo-controlled clinical trial of N-acetylcysteine in dogs with spinal cord trauma from acute intervertebral disc disease. Spine (Phila Pa 1976) 2008, 33(13):1397-1402.
40. Parker A.J., Smith C.W. Lack of functional recovery from spinal cord trauma following dimethylsulphoxide and epsilon amino caproic acid therapy in dogs. Res Vet Sci 1979, 27(2):253-255.
41. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209(2):378-388.
42. Noble L.J., Donovan F., Igarashi T., et al. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002, 22(17):7526-7535.
43. Levine J.M., Ruaux C.G., Bergman R.L., et al. Matrix metalloproteinase-9 activity in the cerebrospinal fluid and serum of dogs with acute spinal cord trauma from intervertebral disk disease. Am J Vet Res 2006, 67(2):283-287.
44. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985, 2(4):299-315.
45. Shechter R., London A., Varol C., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6(7):e1000113.
46. Kigerl K.A., Gensel J.C., Ankeny D.P., et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29(43):13435-13444.
47. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 2009, 119(10):2990-2999.
48. Popovich P., McTigue D. Damage control in the nervous system: beware the immune system in spinal cord injury. Nat Med 2009, 15(7):736-737.
49. Parker A.J., Smith C.W. Functional recovery from spinal cord trauma following dexamethazone and chlorpromazine therapy in dogs. Res Vet Sci 1976, 21(2):246-247.
50. Arias M.J. Treatment of experimental spinal cord injury with TRH, naloxone, and dexamethasone. Surg Neurol 1987, 28(5):335-338.
51. Levine J.M., Levine G.J., Boozer L., et al. Adverse effects and outcome associated with dexamethasone administration in dogs with acute thoracolumbar intervertebral disk herniation: 161 cases (2000-2006). J Am Vet Med Assoc 2008, 232(3):411-417.
52. Ruddle T.L., Allen D.A., Schertel E.R., et al. Outcome and prognostic factors in non-ambulatory Hansen Type I intervertebral disc extrusions: 308 cases. Vet Comp Orthop Traumatol 2006, 19(1):29-34.
53. Beattie M.S. Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol Med 2004, 10(12):580-583.
54. Crowe M.J., Bresnahan J.C., Shuman S.L., et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997, 3(1):73-76.
55. Emery E., Aldana P., Bunge M.B., et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg 1998, 89(6):911-920.
56. Casha S., Yu W.R., Fehlings M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neurosci 2001, 103(1):203-218.
57. Ackery A., Robins S., Fehlings M.G. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 2006, 23(5):604-616.
58. Plunet W.T., Streijger F., Lam C.K., et al. Dietary restriction started after spinal cord injury improves functional recovery. Exp Neurol 2008, 213(1):28-35.
59. Borgens R.B., Bohnert D. Rapid recovery from spinal cord injury after subcutaneously administered polyethylene glycol. J Neurosci Res 2001, 66:1179-1186.
60. Shi R., Borgens R.B. Anatomical repair of nerve membranes in crushed mammalian spinal cord with polyethylene glycol. J Neurocytol 2000, 29:633-643.
61. Shi R., Borgens R.B. Acute repair of crushed guinea pig spinal cord by polyethylene glycol. J Neurophysiol 1999, 81:2406-2414.
62. Laverty P.H., Leskovar A., Breur G.J., et al. A preliminary study of intravenous surfactants in paraplegic dogs: polymer therapy in canine clinical SCI. J Neurotrauma 2004, 21(12):1767-1777.
63. Olby N.J., Harris T., Muñana K., et al. Long term functional outcome of dogs with severe thoracolumbar spinal cord injuries. J Am Vet Med Assoc 2003, 222:762-769.
64. Scott H.W., McKee W.M. Laminectomy for 34 dogs with thoracolumbar intervertebral disc disease and loss of deep pain perception. J Small Anim Pract 1999, 40:417-422.
65. Duval J., Dewey C., Roberts R., et al. Spinal cord swelling as a myelographic indicator of prognosis: a retrospective study in dogs with intervertebral disc disease and loss of deep pain sensation. Vet Surg 1996, 25:6-12.
66. Borgens R.B., Toombs J.P., Breur G., et al. An imposed oscillating electrical field improves the recovery of function in neurologically complete paraplegic dogs. J Neurotrauma 1999, 16(7):639-657.
67. Shapiro S., Borgens R., Pascuzzi R., et al. Oscillating field stimulation for complete spinal cord injury in humans: a phase 1 trial. J Neurosurg Spine 2005, 2(1):3-10. [erratum in: J Neurosurg Spine 2008;8(6):604].
68. Skeen T.M., Olby N.J., Muñana K.R., et al. Spinal arachnoid cysts in 17 dogs. J Am Anim Hosp Assoc 2003, 39(3):271-282.
69. Hannila S.S., Filbin M.T. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol 2008, 209(2):321-332.
70. Fawcett J.W. Overcoming inhibition in the damaged spinal cord. J Neurotrauma 2006, 23(3-4):371-383.
71. Giger R.J., Venkatesh K., Chivatakarn O., et al. Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems. Restor Neurol Neurosci 2008, 26(2-3):97-115.
72. Kubo T., Yamaguchi A., Iwata N., et al. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008, 4(3):605-615.
73. Blight A.R. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989, 22:47-52.
74. Nashmi R., Fehlings M.G. Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 2001, 38:165-191.
75. Blight A.R., Toombs J.P., Bauer M.S., et al. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991, 8:103-119.
76. Hayes K.C., Potter P.J., Wolfe D.L., et al. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994, 11:433-446.
77. Goodman A.D., Cohen J.A., Cross A., et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007, 13:357-368.
78. Olby N.J., Smith D.T., Humphrey J., et al. Pharmacokinetics of 4-aminopyridine derivatives in dogs. J Vet Pharmacol Ther 2009, 32(5):485-491.
79. Rossi S.L., Keirstead H.S. Stem cells and spinal cord regeneration. Curr Opin Biotechnol 2009, 20(5):552-562.
80. Fortun J., Hill C.E., Bunge M.B. Combinatorial strategies with Schwann cell transplantation to improve repair of the injured spinal cord. Neurosci Lett 2009, 456(3):124-132.
81. Ito D., Ibanez C., Ogawa H., et al. Comparison of cell populations derived from canine olfactory bulb and olfactory mucosal cultures. Am J Vet Res 2006, 67(6):1050-1056.
82. Schaffler A., Buchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2008, 25:818-827.
83. Lim J.H., Byeon Y.E., Ryu H.H., et al. Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs. J Vet Sci 2007, 8(3):275-282.
84. Lim J.H., Olby N.J., Mariani C.L. Neural stem cell sources in adult dogs [abstract]. ACVIM Forum. In: Proceedings of ACVIM. J Vet Intern Med 2009, 23:742.
85. Kamishina H., Cheeseman J., Clemmons R. Nestin-positive spheres derived from canine bone marrow stromal cells generate cells with early neuronal and glial phenotypic characteristics. In Vitro Cell Dev Biol Anim 2008, 44:140-144.
86. Milward E.A., Lundberg C.G., Ge B., et al. Isolation and transplantation of multipotential populations of epidermal growth factor-responsive, neural progenitor cells from the canine brain. J Neurosci Res 1997, 50(5):862-871.
87. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.